The Chinese authorities have approved the urgent use of an inactivated drug from Sinopharm (China) for vaccination against COVID-19 children aged 3 to 17 years, the information portal вЂњPenpaiвЂќ reports.
The company received the corresponding permission on July 16. The first and second stages of clinical trials were completed in the central province of Henan. The seroconversion index (production of antibodies by the body) is 100%, the mean geometric antibody titer, and the seroconversion index practically did not differ from the results of adult participants in clinical trials.
Experts noted that according to the results of the tests, the drug proved to be highly safe, no serious side effects were detected. Some participants complained of fever and pain at the injection site. The publication noted that on June 6, the vaccine began to be tested in Abu Dhabi (UAE) on 900 citizens of different nationalities aged from 3 to 17 years.